 |
PDBsum entry 1n0s
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Binding protein
|
PDB id
|
|
|
|
1n0s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proteins
53:121-129
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region.
|
|
I.P.Korndörfer,
G.Beste,
A.Skerra.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The artificial lipocalin FluA with novel specificity toward fluorescein was
derived via combinatorial engineering from the bilin-binding protein, BBP by
exchange of 16 amino acids in the ligand pocket. Here, we describe the crystal
structure of FluA at 2.0 A resolution in the space group P2(1) with two
protein-ligand complexes in the asymmetric unit. In both molecules, the
characteristic beta-barrel architecture with the attached alpha-helix is well
preserved. In contrast, the four loops at one end of the beta-barrel that form
the entrance to the binding site exhibit large conformational deviations from
the wild-type protein, which can be attributed to the sidechain replacements.
Specificity for the new ligand is furnished by hydrophobic packing, charged
sidechain environment, and hydrogen bonds with its hydroxyl groups.
Unexpectedly, fluorescein is bound in a much deeper cavity than biliverdin
IX(gamma) in the natural lipocalin. Triggered by the substituted residues,
unmutated sidechains at the bottom of the binding site adopt conformations that
are quite different from those observed in the BBP, illustrating that not only
the loop region but also the hydrophobic interior of the beta-barrel can be
reshaped for molecular recognition. Particularly, Trp 129 participates in a
tight stacking interaction with the xanthenolone moiety, which may explain the
ultrafast electron transfer that occurs on light excitation of the bound
fluorescein. These structural findings support our concept of using lipocalins
as a scaffold for the engineering of so-called "anticalins" directed
against prescribed targets as an alternative to recombinant antibody fragments.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. The two monomers of FluA in the asymmetric crystal
unit. Each polypeptide chain is shown in a ribbon presentation,
light- and dark-gray, respectively, with its N- and C-terminus
labeled and the fluorescein ligand depicted as a ball-and-stick
model. The intermolecular -sheet
that is formed via association of the loop #3 segments from the
two monomers can be seen at the middle, together with the
position of the crystallographically fixed sulfate ion.
|
 |
Figure 4.
Figure 4. Stereo images with details of the novel
ligand-binding site in FluA. (A) 2F[o]-F[c] electron density for
the bound fluorescein contoured at 1.0 ,
together with sidechains of residues closer than 3.8 Å.
Amino acids that were mutated in FluA (cf. Fig. 1) are colored
dark-green, whereas original residues of BBP are depicted in
light-green. (B) The set of 16 randomly mutated sidechains in
the FluA crystal structure with the complexed fluorescein. (C)
Arrangement of positively charged residues at the entrance to
the ligand pocket of FluA. The three characteristically arranged
Arg side chains (see text) are colored dark-blue. Note that
there is a considerable distance between Arg 95 - whose
sidechain is well defined in the electron density - and the
bound fluorescein along the view axis (distance between the
guanidinium and carboxylate groups: 8.6 Å) such that no
direct contact is formed.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from John Wiley & Sons, Inc.:
Proteins
(2003,
53,
121-129)
copyright 2003.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
H.J.Chiu,
C.Bakolitsa,
A.Skerra,
A.Lomize,
D.Carlton,
M.D.Miller,
S.S.Krishna,
P.Abdubek,
T.Astakhova,
H.L.Axelrod,
T.Clayton,
M.C.Deller,
L.Duan,
J.Feuerhelm,
J.C.Grant,
S.K.Grzechnik,
G.W.Han,
L.Jaroszewski,
K.K.Jin,
H.E.Klock,
M.W.Knuth,
P.Kozbial,
A.Kumar,
D.Marciano,
D.McMullan,
A.T.Morse,
E.Nigoghossian,
L.Okach,
J.Paulsen,
R.Reyes,
C.L.Rife,
H.van den Bedem,
D.Weekes,
Q.Xu,
K.O.Hodgson,
J.Wooley,
M.A.Elsliger,
A.M.Deacon,
A.Godzik,
S.A.Lesley,
and
I.A.Wilson
(2010).
Structure of the first representative of Pfam family PF09410 (DUF2006) reveals a structural signature of the calycin superfamily that suggests a role in lipid metabolism.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
66,
1153-1159.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.L.Mills,
G.Liu,
A.Skerra,
and
T.Szyperski
(2009).
NMR structure and dynamics of the engineered fluorescein-binding lipocalin FluA reveal rigidification of beta-barrel and variable loops upon enthalpy-driven ligand binding.
|
| |
Biochemistry,
48,
7411-7419.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Skerra
(2008).
Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
|
| |
FEBS J,
275,
2677-2683.
|
 |
|
|
|
|
 |
B.Krishnan,
and
L.M.Gierasch
(2008).
Cross-strand split tetra-Cys motifs as structure sensors in a beta-sheet protein.
|
| |
Chem Biol,
15,
1104-1115.
|
 |
|
|
|
|
 |
J.Wiedersich,
S.Köhler,
A.Skerra,
and
J.Friedrich
(2008).
Temperature and pressure dependence of protein stability: the engineered fluorescein-binding lipocalin FluA shows an elliptic phase diagram.
|
| |
Proc Natl Acad Sci U S A,
105,
5756-5761.
|
 |
|
|
|
|
 |
A.M.Hohlbaum,
and
A.Skerra
(2007).
Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.
|
| |
Expert Rev Clin Immunol,
3,
491-501.
|
 |
|
|
|
|
 |
C.Kiss,
H.Fisher,
E.Pesavento,
M.Dai,
R.Valero,
M.Ovecka,
R.Nolan,
M.L.Phipps,
N.Velappan,
L.Chasteen,
J.S.Martinez,
G.S.Waldo,
P.Pavlik,
and
A.R.Bradbury
(2006).
Antibody binding loop insertions as diversity elements.
|
| |
Nucleic Acids Res,
34,
e132.
|
 |
|
|
|
|
 |
R.J.Hosse,
A.Rothe,
and
B.E.Power
(2006).
A new generation of protein display scaffolds for molecular recognition.
|
| |
Protein Sci,
15,
14-27.
|
 |
|
|
|
|
 |
A.Honegger,
S.Spinelli,
C.Cambillau,
and
A.Plückthun
(2005).
A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex.
|
| |
Protein Sci,
14,
2537-2549.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.L.Stokes,
F.Delavoie,
W.J.Rice,
P.Champeil,
D.B.McIntosh,
and
J.J.Lacapère
(2005).
Structural studies of a stabilized phosphoenzyme intermediate of Ca2+-ATPase.
|
| |
J Biol Chem,
280,
18063-18072.
|
 |
|
|
|
|
 |
H.K.Binz,
and
A.Plückthun
(2005).
Engineered proteins as specific binding reagents.
|
| |
Curr Opin Biotechnol,
16,
459-469.
|
 |
|
|
|
|
 |
H.K.Binz,
P.Amstutz,
and
A.Plückthun
(2005).
Engineering novel binding proteins from nonimmunoglobulin domains.
|
| |
Nat Biotechnol,
23,
1257-1268.
|
 |
|
|
|
|
 |
K.Deuschle,
S.Okumoto,
M.Fehr,
L.L.Looger,
L.Kozhukh,
and
W.B.Frommer
(2005).
Construction and optimization of a family of genetically encoded metabolite sensors by semirational protein engineering.
|
| |
Protein Sci,
14,
2304-2314.
|
 |
|
|
|
|
 |
S.Schlehuber,
and
A.Skerra
(2005).
Anticalins in drug development.
|
| |
BioDrugs,
19,
279-288.
|
 |
|
|
|
|
 |
S.Schlehuber,
and
A.Skerra
(2005).
Anticalins as an alternative to antibody technology.
|
| |
Expert Opin Biol Ther,
5,
1453-1462.
|
 |
|
|
|
|
 |
S.Vopel,
H.Mühlbach,
and
A.Skerra
(2005).
Rational engineering of a fluorescein-binding anticalin for improved ligand affinity.
|
| |
Biol Chem,
386,
1097-1104.
|
 |
|
|
|
|
 |
P.Mathonet,
and
J.Fastrez
(2004).
Engineering of non-natural receptors.
|
| |
Curr Opin Struct Biol,
14,
505-511.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |